Tao Sun
Union Hospital(CN)Bengbu Medical College(CN)Capital Medical University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Harbin Institute of Technology(CN)Dalian University of Technology(CN)Nanjing General Hospital of Nanjing Military Command(CN)First Affiliated Hospital of Hunan University of Traditional Chinese Medicine(CN)Ningbo Medical Center Lihuili Hospital(CN)State Key Laboratory of Information Engineering in Surveying Mapping and Remote Sensing(CN)Wuhan Union Hospital(CN)The Affiliated Yongchuan Hospital of Chongqing Medical University(CN)Guang’anmen Hospital(CN)Wenzhou-Kean University(CN)Liaoning Cancer Hospital & Institute(CN)Union Hospital(CN)Beijing Obstetrics and Gynecology Hospital(CN)Huazhong University of Science and Technology(CN)Chongqing Medical University(CN)China Medical University(CN)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer(2021)702 cited
- → Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events(2017)500 cited
- → Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial(2021)378 cited
- → Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial(2021)159 cited
- → Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study(2020)102 cited